AUMOVIO and AWS Join Forces to Transform Autonomous Driving Development
6.1.2026 16:00:00 EET | Business Wire | Press release
AUMOVIO, one of the leading technology and electronics companies, and Amazon Web Services, Inc. (AWS), an Amazon.com, Inc. company (NASDAQ: AMZN), today announced a strategic agreement to help accelerate the development of safer, smarter self-driving vehicles, as well as establishing AWS as AUMOVIO's preferred cloud provider for autonomous driving development.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106574450/en/
Aurora's driverless truck
The collaboration integrates breakthrough agentic and generative AI capabilities directly into AUMOVIO autonomous development and validation workflows—solving one of the automotive industry's biggest bottlenecks by dramatically speeding up how quickly manufacturers can develop, test, and ready their autonomous vehicles for real-world deployment. The new solutions will be used for the first time in a significant customer project: deploying autonomous trucks at scale for Aurora, the leader in self-driving freight.
“Our collaboration with AWS is a cornerstone of our strategy to lead the transformation to autonomous mobility,” said Ismail Dagli, Executive Board member and head of the Autonomous Mobility business area at AUMOVIO. “We are creating a solution that combines cloud infrastructure, AI capabilities, and automotive expertise, efficiently turning data into actionable insights across complex information environments. This collaboration is not only about accelerating development for our customers, but also about helping promote safety, efficiency, and innovation in autonomous driving.”
Developing self-driving vehicles requires processing massive amounts of information—millions of road scenarios, driver behaviors, and safety situations every day. Making sense of all this data quickly and accurately is critical to building vehicles that can help navigate safely in any condition. By combining AUMOVIO's deep automotive technology expertise with AWS's advanced cloud infrastructure and AI capabilities including Amazon Bedrock, the collaboration helps create scalable solutions that rapidly process this flood of information. These solutions help identify critical safety patterns and enable more rapid improvements in vehicle hazard detection that would traditionally take years.
"The automotive industry is at an inflection point where traditional development methods simply can't keep pace," said Jeremy McClain, head of System & Software Business at AUMOVIO's Autonomous Mobility business area. "Our customers are racing to bring autonomous technology to market without compromising on safety, and AWS's capabilities allow us to help them do both—move faster while maintaining the rigorous safety standards the industry demands."
AI That Speaks Your Language
The collaboration harnesses artificial intelligence to transform how autonomous vehicle systems are created. Engineers must test autonomous vehicles against millions of recorded driving scenarios to help ensure safety—a process that traditionally meant spending weeks manually searching through this data. Now they can simply ask questions in plain language—like "show me all cases where pedestrians entered the roadway at night in rain"—and get instant results. The AI helps surface critical safety scenarios and rare edge cases for further testing, freeing engineers to focus more on development rather than data management.
"At AWS, we believe the future of autonomous mobility isn't just about technology—it's about enabling our partners to deliver on the promise of safer, more efficient transportation at scale,” said Ozgur Tohumcu, general manager of Automotive and Manufacturing at AWS. “Our collaboration with AUMOVIO and Aurora exemplifies this vision, combining AWS's AI and cloud infrastructure with AUMOVIO's automotive expertise to help Aurora scale autonomous trucking while maintaining rigorous safety standards."
Powering the Next Generation of Autonomous Trucks with Aurora
AWS is helping AUMOVIO accelerate the deployment of autonomous trucks at scale, which will make the movement of freight safer and more efficient. By partnering with Aurora—the first company to launch driverless trucks in the U.S.—AUMOVIO is co-developing and manufacturing an industrialized and scalable generation of the Aurora Driver. When production begins in 2027, AUMOVIO will also provide a specialized backup computer to ensure safety if the primary system fails.
The Aurora Driver is developed through a rigorous validation process, which includes extensive virtual testing to ensure safety and reliability. AWS supports this effort by processing enormous volumes of sensor data, ensuring the Aurora Driver can safely navigate complex real-world scenarios. As part of the validation process for driverless operations, the Aurora Driver has satisfied more than 10,000 requirements and passed 4.5 million tests.
“Working with AWS to power the development of the Aurora Driver was critical to becoming the first company to launch driverless trucks in the U.S.,” said Matt Ellis, senior vice president of Software Engineering at Aurora. “Assembling an ecosystem of world-class partners to deliver the Aurora Driver at scale will continue to be key to strengthening our leadership in autonomous freight.”
The future of transportation depends on getting autonomous vehicles right—balancing rapid innovation with uncompromising safety. Through this collaboration, AUMOVIO and AWS are providing the industry with the solutions to help achieve both.
About AWS
Amazon Web Services (AWS) is guided by customer obsession, pace of innovation, commitment to operational excellence, and long-term thinking. By democratizing technology for nearly two decades and making cloud computing and generative AI accessible to organizations of every size and industry, AWS has built one of the fastest-growing enterprise technology businesses in history. Millions of customers trust AWS to accelerate innovation, transform their businesses, and shape the future. With the most comprehensive AI capabilities and global infrastructure footprint, AWS empowers builders to turn big ideas into reality. Learn more at aws.amazon.com and follow @AWSNewsroom.
About AUMOVIO
Since its spin-off in September 2025, AUMOVIO continues the business of the former Continental group sector Automotive as an independent company. The technology and electronics company offers a wide-ranging portfolio that makes mobility safe, exciting, connected, and autonomous. This includes sensor solutions, displays, braking, and comfort systems, as well as comprehensive expertise in software, architecture platforms, and assistance systems for software-defined vehicles. In the fiscal year 2024, the business areas, which now belong to AUMOVIO, generated sales of 19.6 billion Euro. The company is headquartered in Frankfurt, Germany and has over 86,000 employees in more than 100 locations worldwide.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260106574450/en/
Contacts
Amazon.com, Inc.
Media Hotline
Amazon-pr@amazon.com
www.amazon.com/pr -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.amazon.com%
2Fpr&esheet=54389471&newsitemid=20260106574450&lan=en-US&anchor=www.amazon.com%2
Fpr&index=4&md5=8992b232011ff0fd915a5e29444baff5
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom